Topic: Eye
Conditions
Interventions
This study aims to determine whether genotypes for single nucleotide polymorphisms (SNPs) in the complement factor H, HTRA1 and VEGF genes can predict response to treatment with ranibizumab in patient
Sponsors
Leeds Teaching Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged over 65 years, either sex 2. Affected with ARM 3. Currently under treatment with ranibizumab (Lucentis) 4. Patients with lesions of greatest linear diameter less than 5400 microns
Exclusion criteria
Exclusion criteria: 1. Patients with poor general health 2. Patients with other eye pathology likely to affect response to treatment 3. Patients with lesions of greatest linear diameter greater than 5400 microns 4. Patients currently being treated with other anti-VEGF agents (systemic or ocular)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association of visual acuity letter score change after 6 months of treatment with intra-vitreal ranibizumab and CFH, HTRA1 and VEGF genotype. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Association of visual acuity letter score change after 6 months of treatment with intra-vitreal ranibizumab and baseline visual acuity 2. Smoking history 3. Sex 4. Lesion type 5. Number of injections 6. Prior treatment status | — |
Countries
United Kingdom
Outcome results
None listed